35. An integrative clinical decision support tool for next-generation sequencing and cytogenetics assays in hematological cancers

Introduction: Sanger sequencing and karyotyping are traditionally used to detect molecular alterations in hematological cancers that inform diagnosis and treatment. Recently, new biomarkers have expanded the scope of molecular testing. To address the need for broader profiling, we developed a next-generation sequencing (NGS) assay that detects alterations in over 60 hematological cancer genes and a cytogenetics assay to detect chromosomal alterations. Furthermore, we developed a clinical decision support tool that integrates results from both platforms into a single report.